Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumour × L19-IL2 immunocytokine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Solid Tumour 1 Neoplasm Metastasis 1

Interventions

capivasertib 1 atezolizumab 1 N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide 1 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 1 Midazolam 1 L19-IL2 immunocytokine 1 Itraconazole 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02086721 2017-05-31

L19-IL2

Maastricht Radiation Oncology

Phase 1 Completed

Other solid neoplasm

Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡